Tasrif Pharmaceutical
Discovering Novel Immunotherapeutics Against Cancer
Tasrif Pharmaceutical is a preclinical stage company and none of the products are FDA approved.
Who We Are
Founded in 2018, Tasrif Pharmaceutical’s focus is on novel immunotherapeutic targeting of the poliovirus receptor (CD155).
Our Target: CD155
Tasrif Pharmaceutical has developed and patented a panel of monoclonal antibodies against CD155 humanized by Abzena Composite Human Platform.
Platform Technology
ADCs, Bispecifics, Checkpoint Inhibitor, T-Cell Engager, CAR-T and CAR-NK Cells targeting CD155 for the treatment of cancer.
Tasrif Pharmaceutical 